Result of AGM, GM & Further re Share Consolidation

Cyprotex PLC

("Cyprotex" or "the Company")

Result of AGM, Result of GM

& Further Re. Share Consolidation

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces that at the Company's Annual General Meeting today all the resolutions were duly passed.

In addition at the Company's General Meeting, also held today, to approve the proposed share consolidation all resolutions were passed. Under the Share Consolidation every 10 existing ordinary shares will be consolidated into one new ordinary share, with any fractional entitlements arising from the Share Consolidation being aggregated and sold in the market on behalf of the relevant Shareholders and the proceeds donated to charity.

The rights attaching to the New Ordinary Shares will be identical in all respects to those of the Existing Ordinary Shares.

Application has been made for the 22,434,056 New Ordinary Shares of £0.01 each to be admitted to trading on AIM. Dealings are expected to commence on 28 July 2014. The New Ordinary Shares will trade under the ISIN: GB00BP25RZ14 and SEDOL: BP25RZ1.

The Definitions which apply in the Circular have been used in this announcement.

For further information:

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo,MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.